Democrats Meet With Trump to Discuss Drug Pricing
Representatives Elijah Cummings, D-Maryland, and Peter Welch, D-Vermont, met with President Donald Trump yesterday to form an unlikely alliance against the high cost of prescription drugs. The legislators presented a bill that would allow Medicare to negotiate prices, an idea that Trump had supported during his campaign. According to Kaiser Health News, Cummings commended the president as “aware of the problem” and “enthusiastic” in remarks after the meeting.
Replacement Bill Isn’t Called “Trumpcare,” White House Insists
The inevitable nickname of “Trumpcare” for the Republican bill to replace Obamacare has been greeted with resistance by the Trump administration, Politico reports. Democrats have seized on the term, but officials want the bill to be branded by its official name, the American Health Care Act, as they don’t want it associated with the negative connotations of Obamacare among conservatives. HHS secretary Tom Price offered up a slightly catchier alternative: “I prefer to call it PatientCare,” he said at a White House press briefing.
FDA Public Meeting Attempts to Define “Healthy” Foods
A battle that started over the word “healthy” on KIND bar labels has spurred the FDA to hold a public meeting in hopes of determining what actually makes a food healthy, reported STAT. Today’s meeting will unite nutritionists, food company representatives, and others to discuss topics like consumers’ perceptions of healthy foods and whether health claims should be based on nutrient content.
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More